Fan Zhu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Fan Zhu has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
Hani Md Ashamalla
From the Department of Radiation Oncology, New York–Presbyterian Brooklyn Methodist Hospital, Brooklyn, New York, NY
2 shared publicationsHaoyu Wang
From the Department of Radiation Oncology, New York–Presbyterian Brooklyn Methodist Hospital, Brooklyn, New York, NY
2 shared publications- Haoyu Wang
Department of Pulmonary and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, China
2 shared publications Adel Mbbch Guirguis
From the Department of Radiation Oncology, New York–Presbyterian Brooklyn Methodist Hospital, Brooklyn, NY
1 shared publication- An Tai
Department of Radiation Oncology Medical College of Wisconsin Milwaukee Wisconsin USA
1 shared publication - Elizabeth M. Gore
The Medical College of Wisconsin and Milwaukee VAMC Milwaukee Wisconsin USA
1 shared publication
Latest Publications
- 1 May 2025
- Published by Wolters Kluwer Health in The Cancer Journal
- Vol. 31 (3)
Personalizing Approaches to Management of HPV+ Oropharyngeal Cancer
HPV+ oropharyngeal cancer represents a unique disease entity in the realm of head and neck cancer with distinct incidence and prevalence, pathogenesis, and treatment outcome. Management of this disease needs to be personalized in consideration of a combination of factors of both patient and disease characteristics. Overall outcomes in this patient population are excellent. Therefore, late side effects of treatment are gaining increasing importance and attention. Here we present a brief overview of personalized approaches for this patient population, illustrated by a discussion of several cases.
- 1 May 2025
- Published by Wolters Kluwer Health in The Cancer Journal
- Vol. 31 (3)
Personalizing Approaches to Management of HPV+ Oropharyngeal Cancer
HPV+ oropharyngeal cancer represents a unique disease entity in the realm of head and neck cancer with distinct incidence and prevalence, pathogenesis, and treatment outcome. Management of this disease needs to be personalized in consideration of a combination of factors of both patient and disease characteristics. Overall outcomes in this patient population are excellent. Therefore, late side effects of treatment are gaining increasing importance and attention. Here we present a brief overview of personalized approaches for this patient population, illustrated by a discussion of several cases.
- 22 January 2025
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 205, 110741
Radiobiologically equivalent deformable dose mapping for re-irradiation planning: Implementation, robustness, and dosimetric benefits
- 22 January 2025
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 205, 110741
Radiobiologically equivalent deformable dose mapping for re-irradiation planning: Implementation, robustness, and dosimetric benefits
- 24 December 2022
- Published by Springer Nature in Journal of Genetics
- Vol. 102 (1) , 1-13
LncRNA TTN-AS1 exacerbates extracellular matrix accumulation via miR-493-3p/FOXP2 axis in diabetic nephropathy
Diabetic nephropathy (DN), a common cause of chronic renal failure and end-stage renal disease, leads to a high mortality. However, the role of TTN-AS1 in extracellular matrix (ECM) accumulation during DN remains unclear. In our study, TTN-AS1 exhibited high expression in high glucose-treated mesangial cells, and TTN-AS1 silencing alleviated high glucose-induced ECM accumulation in mesangial cells. Additionally, animal study revealed that TTN-AS1 was upregulated in renal tissues of DN rats, and TTN-AS1 knockdown mitigated renal injury of DN rats. Mechanistically, TTN-AS1 was validated to bind to miR-493-3p, and miR-493-3p targeted forkhead box P2 (FOXP2) 3′untranslated region in mesangial cells. TTN-AS1 interacted with miR-493-3p to upregulate FOXP2 in vitro and in vivo. Moreover, FOXP2 overexpression counteracted the effects of TTN-AS1 silencing on the ECM accumulation. In conclusion, TTN-AS1 exacerbated ECM accumulation via the miR‐493-3p/FOXP2 axis during DN development. This research may provide a potential new direction for DN treatment.
- 24 December 2022
- Published by Springer Nature in Journal of Genetics
- Vol. 102 (1) , 1-13
LncRNA TTN-AS1 exacerbates extracellular matrix accumulation via miR-493-3p/FOXP2 axis in diabetic nephropathy
Diabetic nephropathy (DN), a common cause of chronic renal failure and end-stage renal disease, leads to a high mortality. However, the role of TTN-AS1 in extracellular matrix (ECM) accumulation during DN remains unclear. In our study, TTN-AS1 exhibited high expression in high glucose-treated mesangial cells, and TTN-AS1 silencing alleviated high glucose-induced ECM accumulation in mesangial cells. Additionally, animal study revealed that TTN-AS1 was upregulated in renal tissues of DN rats, and TTN-AS1 knockdown mitigated renal injury of DN rats. Mechanistically, TTN-AS1 was validated to bind to miR-493-3p, and miR-493-3p targeted forkhead box P2 (FOXP2) 3′untranslated region in mesangial cells. TTN-AS1 interacted with miR-493-3p to upregulate FOXP2 in vitro and in vivo. Moreover, FOXP2 overexpression counteracted the effects of TTN-AS1 silencing on the ECM accumulation. In conclusion, TTN-AS1 exacerbated ECM accumulation via the miR‐493-3p/FOXP2 axis during DN development. This research may provide a potential new direction for DN treatment.
- 11 May 2022
- Published by Elsevier in Clinical Lung Cancer
- Vol. 23 (6) , e384-e393
The Significance of Lymph Node Ratio and Total Lymph Nodes Examined in Determining the Indications of Adjuvant Radiation in pN2 Non–small Cell Lung Cancer
- 11 May 2022
- Published by Elsevier in Clinical Lung Cancer
- Vol. 23 (6) , e384-e393
The Significance of Lymph Node Ratio and Total Lymph Nodes Examined in Determining the Indications of Adjuvant Radiation in pN2 Non–small Cell Lung Cancer
- 13 October 2020
- Published by Wolters Kluwer Health in Pancreas
- Vol. 49 (10) , 1355-1363
Racial and Socioeconomic Disparities in the Treatments and Outcomes of Pancreatic Cancer Among Different Treatment Facility Types
Objectives: The aim of this study was to investigate racial and socioeconomic disparities for patients with pancreatic cancer across different facility types. Methods: The National Cancer Database was queried for pancreatic cancer cases from 2004 to 2015. Along with propensity score matching analysis, multivariate logistic and Cox model were used to assess effects of facility type, race, elements of socioeconomics on receipt of treatment, time to treatment, and overall survival, separately. Results: Among 223,465 patients, 44.6%, 42.1%, and 13.3% were treated at academic, community, and integrated facilities, respectively. Private insurance was associated with more treatment (odds ratio, 1.41; P < 0.001) and better survival [hazards ratio (HR), 0.84; P < 0.001]. Higher education was associated with earlier treatment (HR, 1.09; P < 0.001). African Americans had less treatment (odds ratio, 0.97; P = 0.04) and delayed treatment (HR, 0.89; P < 0.001) despite later stage at diagnosis. After adjusting for socioeconomic status, African Americans had similar survival (HR, 0.99; P = 0.11) overall and improved survival (HR, 0.95; P = 0.016) at integrated facilities. Conclusions: Higher socioeconomic status was associated with better treatment and survival. After adjusting for socioeconomic disparities, race did not affect survival. Less racial disparity was observed at integrated facilities.
- 13 October 2020
- Published by Wolters Kluwer Health in Pancreas
- Vol. 49 (10) , 1355-1363
Racial and Socioeconomic Disparities in the Treatments and Outcomes of Pancreatic Cancer Among Different Treatment Facility Types
Objectives: The aim of this study was to investigate racial and socioeconomic disparities for patients with pancreatic cancer across different facility types. Methods: The National Cancer Database was queried for pancreatic cancer cases from 2004 to 2015. Along with propensity score matching analysis, multivariate logistic and Cox model were used to assess effects of facility type, race, elements of socioeconomics on receipt of treatment, time to treatment, and overall survival, separately. Results: Among 223,465 patients, 44.6%, 42.1%, and 13.3% were treated at academic, community, and integrated facilities, respectively. Private insurance was associated with more treatment (odds ratio, 1.41; P < 0.001) and better survival [hazards ratio (HR), 0.84; P < 0.001]. Higher education was associated with earlier treatment (HR, 1.09; P < 0.001). African Americans had less treatment (odds ratio, 0.97; P = 0.04) and delayed treatment (HR, 0.89; P < 0.001) despite later stage at diagnosis. After adjusting for socioeconomic status, African Americans had similar survival (HR, 0.99; P = 0.11) overall and improved survival (HR, 0.95; P = 0.016) at integrated facilities. Conclusions: Higher socioeconomic status was associated with better treatment and survival. After adjusting for socioeconomic disparities, race did not affect survival. Less racial disparity was observed at integrated facilities.
- 4 March 2020
- Published by Wolters Kluwer Health in Pancreas
- Vol. 49 (3) , 435-441
The Value of Total Lymph Nodes Examined and Number of Positive Lymph Nodes in Determining the Role of Adjuvant Radiation in Pancreatic Cancer Patients
Objectives The aim of this study was to determine the survival benefits by adjuvant radiation therapy (RT) in pancreatic cancer patients with different total lymph nodes examined (TNE), number of positive lymph nodes (NPN), and lymph nodes ratio (LNR). Methods National Cancer Database was queried for nonmetastatic pancreatic cancer patients from 2004 to 2015. Cox models were utilized. Interaction terms were applied to evaluate the effect of RT in different NPN, LNR, and margin strata. Multivariate analysis was performed. Results Of 19,759 patients identified, 10,910 patients qualified. Compared with TNE of 1 to 9, TNE of 10 to 14, 15 to 19, 20 to 24, and 25 or greater had progressive overall survival (OS) benefits. Adjuvant RT had similar OS benefits among them. In negative margin patients, adjuvant RT improved OS when NPN was 2 to 3 (hazards ratio [HR], 0.84; P = 0.01) or LNR was 0.15 to 0.25 (HR, 0.79; P = 0.002). In positive margin patients, adjuvant RT nonsignificantly improved OS when NPN was 1 to 3 (HR, 0.89; P = 0.36) or when NPN was 4 or greater (HR, 0.79; P = 0.07). Conclusions Higher TNE correlates with better survival. Adjuvant RT may not compensate for inadequate lymph node dissection. Adjuvant RT improves survival in negative-margin patients with 2 to 3 positive lymph nodes or LNR of 0.15 to 0.25.
- 4 March 2020
- Published by Wolters Kluwer Health in Pancreas
- Vol. 49 (3) , 435-441
The Value of Total Lymph Nodes Examined and Number of Positive Lymph Nodes in Determining the Role of Adjuvant Radiation in Pancreatic Cancer Patients
Objectives The aim of this study was to determine the survival benefits by adjuvant radiation therapy (RT) in pancreatic cancer patients with different total lymph nodes examined (TNE), number of positive lymph nodes (NPN), and lymph nodes ratio (LNR). Methods National Cancer Database was queried for nonmetastatic pancreatic cancer patients from 2004 to 2015. Cox models were utilized. Interaction terms were applied to evaluate the effect of RT in different NPN, LNR, and margin strata. Multivariate analysis was performed. Results Of 19,759 patients identified, 10,910 patients qualified. Compared with TNE of 1 to 9, TNE of 10 to 14, 15 to 19, 20 to 24, and 25 or greater had progressive overall survival (OS) benefits. Adjuvant RT had similar OS benefits among them. In negative margin patients, adjuvant RT improved OS when NPN was 2 to 3 (hazards ratio [HR], 0.84; P = 0.01) or LNR was 0.15 to 0.25 (HR, 0.79; P = 0.002). In positive margin patients, adjuvant RT nonsignificantly improved OS when NPN was 1 to 3 (HR, 0.89; P = 0.36) or when NPN was 4 or greater (HR, 0.79; P = 0.07). Conclusions Higher TNE correlates with better survival. Adjuvant RT may not compensate for inadequate lymph node dissection. Adjuvant RT improves survival in negative-margin patients with 2 to 3 positive lymph nodes or LNR of 0.15 to 0.25.